Cargando…
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
Over the last 25 years, inhibition of Janus kinases (JAKs) has been pursued as a modality for treating various immune and inflammatory disorders. While the clinical development of JAK inhibitors (jakinibs) began with the investigation of their use in allogeneic transplantation, their widest successf...
Autores principales: | Alexander, Madison, Luo, Yiming, Raimondi, Giorgio, O’Shea, John J., Gadina, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779366/ https://www.ncbi.nlm.nih.gov/pubmed/35056105 http://dx.doi.org/10.3390/ph15010048 |
Ejemplares similares
-
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
por: T. Virtanen, Anniina, et al.
Publicado: (2019) -
Engineered protein and Jakinib nanoplatform with extraordinary rheumatoid arthritis treatment
por: Li, Yuanxin, et al.
Publicado: (2023) -
Kinase inhibitors in the treatment of immune-mediated disease
por: Kontzias, Apostolos, et al.
Publicado: (2012) -
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
por: Seal, Rishav, et al.
Publicado: (2023) -
A Case of SAPHO Syndrome Complicated by Uveitis with Good Response to Both TNF Inhibitor and JAKinib
por: Baisya, Ritasman, et al.
Publicado: (2023)